MiNK Therapeutics Q2 Results: Financials and Clinical Updates
MiNK Therapeutics, Inc. will report Q2 2026 financial results on August 13, 2026. The earnings call will feature updates on agenT-797, including new clinical data for acute lung injury and the launch of a named-patient program. Investors can join the live webcast or dial-in to hear management discuss these strategic developments alongside the quarterly financial performance.
*this image is generated using AI for illustrative purposes only.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The announcement provides investors with a timeline for reviewing the company’s latest fiscal performance while simultaneously highlighting significant clinical advancements for its lead therapy candidate, agenT-797, in the treatment of acute lung injury.
The company will host a conference call and webcast at 8:30 AM ET on August 13, 2026, to discuss the financial results and provide a broader corporate update. Management will focus on the clinical progress of agenT-797, an off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy. The session is expected to unveil new clinical data regarding the treatment’s efficacy in patients with pulmonary injury, alongside operational details concerning the launch of MiNK’s named-patient program.
Conference Call Details
Investors and analysts can access the live event through the following dial-in information:
| Dial-In Option | Number | Conference ID |
|---|---|---|
| United States - New York | (646) 307-1963 | 8767945 |
| USA & Canada - Toll-Free | (800) 715-9871 | 8767945 |
A live webcast of the conference call will be accessible via the Events & Presentations page on the company’s website. A replay of the event will also be available following the conclusion of the call.
Clinical Pipeline Context
MiNK Therapeutics specializes in developing allogeneic iNKT cell therapies and precision immune modulators designed to restore immune balance. Its proprietary platform bridges innate and adaptive immunity to address conditions such as cancer, autoimmune disease, and immune collapse.
AgenT-797 is currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. The upcoming data release represents a key milestone in evaluating the therapy’s potential in acute lung injury, a condition characterized by severe inflammation and immune dysregulation. The launch of the named-patient program further signals the company’s strategy to expand access to its investigational therapies outside of standard clinical trial settings.
What the Numbers Show
While specific financial metrics such as revenue, net profit, or cash position are not disclosed in this preliminary announcement, the timing of the results release coincides with material clinical developments. For clinical-stage biopharmaceutical companies, investor sentiment is often driven by pipeline progress rather than near-term profitability. The inclusion of new clinical data for agenT-797 in the earnings call agenda suggests that operational milestones may carry equal weight to financial performance in assessing the company’s current valuation drivers.
How might the efficacy data for agenT-797 in acute lung injury influence MiNK's valuation relative to its cash burn rate and funding runway?
What regulatory hurdles or FDA feedback could impact the expansion of the named-patient program beyond its current scope?
Could the success of agenT-797 in pulmonary injury accelerate clinical timelines for its other indications, such as solid tumors or GvHD?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
